# A Multicenter Study to Evaluate the Efficacy and Safety of Cinryze® for the Treatment of Acute Antibody-mediated Rejection in Participants With Kidney Transplant

> **NCT02547220** · PHASE3 · TERMINATED · sponsor: **Shire** · enrollment: 39 (actual)

## Conditions studied

- Acute Antibody-Mediated Rejection (AMR)

## Interventions

- **BIOLOGICAL:** Cinryze®
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02547220
- **Lead sponsor:** Shire
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-05-20
- **Primary completion:** 2019-05-31
- **Final completion:** 2019-05-31
- **Target enrollment:** 39 (ACTUAL)
- **Why stopped:** Following a pre-scheduled interim analysis performed by the DMC, it was determined that the study met the pre-specified criteria for futility.
- **Last updated:** 2020-07-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02547220

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02547220, "A Multicenter Study to Evaluate the Efficacy and Safety of Cinryze® for the Treatment of Acute Antibody-mediated Rejection in Participants With Kidney Transplant". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02547220. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*